Asset Advisors Corp buys $6,843,729 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Asset Advisors Corp scooped up 7,000 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 102,805 shares of AbbVie Inc which is valued at $6,843,729.AbbVie Inc makes up approximately 1.42% of Asset Advisors Corp’s portfolio.

Other Hedge Funds, Including , Reilly Financial Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 281 additional shares and now holds a total of 3,069 shares of AbbVie Inc which is valued at $204,303. AbbVie Inc makes up approx 0.04% of Reilly Financial Advisors’s portfolio.Hanson Doremus Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 35 additional shares and now holds a total of 5,662 shares of AbbVie Inc which is valued at $374,994. AbbVie Inc makes up approx 0.16% of Hanson Doremus Investment Management’s portfolio.Montag Caldwell reduced its stake in ABBV by selling 1,950 shares or 7.38% in the most recent quarter. The Hedge Fund company now holds 24,479 shares of ABBV which is valued at $1,621,244. AbbVie Inc makes up approx 0.03% of Montag Caldwell’s portfolio.Forte Capital Adv boosted its stake in ABBV in the latest quarter, The investment management firm added 1,365 additional shares and now holds a total of 13,691 shares of AbbVie Inc which is valued at $886,766. AbbVie Inc makes up approx 0.33% of Forte Capital Adv’s portfolio.West Oak Capital boosted its stake in ABBV in the latest quarter, The investment management firm added 407 additional shares and now holds a total of 14,882 shares of AbbVie Inc which is valued at $954,829. AbbVie Inc makes up approx 0.68% of West Oak Capital’s portfolio.

AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.